Pharvaris Shares Soar 79% on Hereditary Angioedema Treatment PHVS416 Data
December 08 2022 - 10:35AM
Dow Jones News
By Denny Jacob
Pharvaris NV shares soared 79%, to $4.50, in early trading after
the company said data on PHVS416 demonstrated statistically
significant results for treatment of hereditary angioedema, a
hereditary condition that causes recurrent swelling.
Top-line data from the Phase 2 study of PHVS416 for the
prophylactic treatment of hereditary angioedema is expected in the
second half of 2023, said Chief Executive Berndt Modig. Data from
the proof-of-concept study is expected to inform the design of
expected Phase 3 utilizing PHVS719, an investigational treatment
currently in Phase 1 clinical development for hereditary
angioedema.
The clinical-stage biopharmaceutical company also said it is
continuing to work with the U.S. Food and Drug Administration to
resolve holds on clinical trials for PHA121, which the company
describes as a competitive antagonist of the bradykinin B2
receptor.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
December 08, 2022 10:20 ET (15:20 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Pharvaris NV (NASDAQ:PHVS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Pharvaris NV (NASDAQ:PHVS)
Historical Stock Chart
From Apr 2023 to Apr 2024
